Both in the context of exclusively dietary interventions and after bariatric surgery or treatment with GLP(glucagon-like peptide)-1 analogs, there is not only a reduction in weight, but also a loss of muscle mass to varying degrees. A differentiated clinical examination shows that this loss does not necessarily equate to a functional deterioration.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Microbiome, inflammaging and affective/cognitive health
Gut-brain axis in old age
- Vitiligo - the level of suffering should not be underestimated
A lot can be achieved therapeutically nowadays
- Patient-centered rounds in medicine
Aligning care with the patient
- Adrenogenital syndrome
Clinical care from birth to adulthood
- Communication between hospitals and outpatient care
How does a digital clinical information system prove itself in everyday practice?
- Acute myeloid leukemia
Treatment decisions between MRD monitoring, transplantation and CAR-T cells
- Psoriasis and metabolic comorbidities: new study data
GLP-1RAs showed a valuable dual benefit
- Heart failure: combination of four as "Guideline-Directed Medical Therapy"